C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin A nephropathy

CURRENT STATUS: ACCEPTED

BMC Nephrology

Yue Xing
Tianjin Medical University General Hospital
ORCID: 0000-0002-4583-8347

Lina Li
Tianjin Medical University General Hospital

Yaru Zhang
Tianjin Medical University General Hospital

Fanghao Wang
Tianjin Medical University General Hospital

Dandan He
Tianjin Medical University General Hospital

Youxia Liu ✉️ 5liuyouxia@163.com
Corresponding Author

Junya Jia
Tianjin Medical University General Hospital

Tiekun Yan
Tianjin Medical University General Hospital

Shan Lin
Tianjin Medical University General Hospital

DOI:
10.21203/rs.2.14899/v1

SUBJECT AREAS
Urology & Nephrology

KEYWORDS
C1GALT1, immunoglobulin A nephropathy
Abstract

Background

More and more studies demonstrated that genetic variation at C1GALT1 influences Gd-IgA1 level in IgAN. However, whether the expression of $\beta_1$, 3-galactosyltransferase ($\beta_1$, 3Gal-T) was influenced may provide insights into how Gd-IgA1 levels are controlled in IgAN.

Methods

Thirty IgAN patients diagnosed in Tianjin Medical University General Hospital from April to September 2018 and 30 healthy volunteers whose age and gender matched with patients were enrolled in this study. Total Gd-IgA1 levels in plasma were determined by ELISA and C1GALT1 levels were determined by RT-PCR. Four databases (PubMed, EMBASE, CNKI, WanFang Medical Network) were searched to identify eligible studies that evaluated a difference in the expression of C1GALT1 in IgAN patients compared with total controls (non-IgAN and health controls). The C1GALT1C1 expression levels, which was indispensable to $\beta_1$, 3Gal-T of IgA1, was also been compared.

Results

Gd-IgA1 levels were remarkable higher in IgAN patients compared with healthy control. The expression levels of C1GALT1 gene were remarkably down-regulated in IgAN patients compared with healthy control. And the mRNA level of C1GALT1 was inversely correlated to Gd-IgA1 levels. In meta-analysis, six articles including 316 participants that analyzed the expression of $\beta_1$, 3Gal-T were met inclusion criteria. There was no significant difference in the expression of C1GALT1 between IgAN patients compared with controls. And we found patients with IgAN had lower levels of C1GALT1 gene expression in the B cells compared to controls. The C1GALT1C1 levels in the IgAN patients were not different from the levels in the control group, which were unchanged no matter according to
different ethnic population, different control group and different cell source. Two studies including 46 persons compared enzymatic activity of β1, 3Gal-T in B cells, and the result showed the β1, 3Gal-T activity was decreased in B cells.

Conclusions

We found expression levels of C1GALT1 were remarkably downregulated in IgAN patients and negatively correlated with higher levels of Gd-IgA1. Subsequent meta-analysis validated the low expression and activity of β1, 3Gal-T in B cells in patients with IgAN. However, there was no apparent disparity in the aspect of C1GALT1C1 expression between IgAN and control groups.

Background

IgA nephropathy (IgAN) is a common primary glomerular nephritis, which is considered to be a progressive disease characterized by a gradually decreasing glomerular filtration rate (GFR). The end-stage renal disease (ESRD) events happened in 15% to 20% of patients within 10 years[1, 2]. In the circulation of most patients with IgAN, galactose-deficient IgA1 (Gd-IgA1) and its corresponding autoantibodies are elevated and correlated with increased risk of disease progression. More and more studies demonstrated that genetic variation at C1GALT1 influences Gd-IgA1 level in IgAN[3]. C1GALT1 encodes β1, 3 galactosyltransferase (β1, 3Gal-T) enzyme which is important in O-galactosylation of glycoproteins. Whether β1, 3Gal-T was influenced may provide insights into how Gd-IgA1 levels are controlled. Some studies confirmed C1GALT1 gene expression level was significantly lower in IgAN patients than that of the control[4], however, the results of Qin W et al did not support this view[5]. Enzyme activity was also compared between IgAN and control in several studies. These studies have yielded inconsistent results. Cosmc, encoded by C1GALT1C1, is core β1, 3Gal-T specific chaperone, and important for IgA1 glycosylation. Cosmc expression was previously reported to be down-regulated and
associated with IgA1 glycosylation. Therefore, we comparatively assessed whether C1GALT1 down-regulated expression induced IgA1 aberrant glycosylation in IgAN and performed a meta-analysis to explore the expression and activity of β1, 3Gal-T in IgAN.

Methods

Subjects and Data Collection

Thirty IgAN patients diagnosed in Tianjin Medical University General Hospital from April to September 2018, were enrolled in this study. The diagnosis was based on the deposition of IgA in the glomerular mesangium by immunofluorescence detection, as well as the lack of clinical or serological evidence of other inflammatory conditions, such as Henoch Schoenlein purpura, systemic lupus erythematosus. At the same time, 30 healthy volunteers whose age and gender matched with patients were recruited. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine (CKD-EPI) equation. The histological lesions were classified according to Oxford classification system.

Plasma was collected from all individuals in this study, for patients at the time of renal biopsy. The plasma samples were stored in aliquots at –80°C for the subsequent use. Clinical information, including age, gender, 24-hour urine protein excretion, blood pressure and total IgA levels, were collected at the time of renal biopsy.

Assay for Gd-IgA1

Plasma Gd-IgA1 levels were detected using ELISA kit according to the manufacturer’s specifications (IBL, Japan)[6]. Plasma samples were diluted in proportions of 1:50 with EIA buffer and incubation for 60min at R. T. with plate lid. Then washing four times with wash buffer prepared labeled antibody were incubated for 30min. Plates were washed and added 50ul TMA solution incubation for 30min in dark. At last, the color reaction was stopped and the absorbance was measured at 450/625 nm with an EL312 Bio-Kinetics
microplate reader (Bio-Tek Instruments, Winooski, VT).

**B lymphocytes Isolation**

About 5 mL venous blood sample was taken into ethylenediaminetetraacetic acid (EDTA) anticoagulated tubes. Peripheral blood mononuclear cells (PBMCs) were separated by density-gradient centrifugation on Ficoll (TBD, China), then washed three times with phosphatebuffered saline (PBS) and resuspended in PBS + 1% bovine serum albumin (BSA). Peripheral B lymphocytes were isolated using CD19 positive magnetic beads (Miltenyi Biotec, USA) according to the manufacturer’s instructions.

**RNA Extraction**

Total cellular RNA was extracted from CD19 positive B lymphocytes using the TRIZOL Reagent (Invitrogen, USA). RNA quantity was determined using NanoDrop ND-1000 spectrophotometer. cDNA was synthesized using 300 ng total RNA with revert first-strand cDNA kit according to manufacturer’s protocol (Promega, USA).

**Quantitative Reverse Transcription PCR (RT-PCR)**

cDNA was amplified with a 20 µL reaction mixture using SYBR Green PCR Master Mix (Roche, USA) in an Applied Biosystem 7500 Real-Time PCR System. GAPDH served as the endogenous control. The primer sequences were listed in Table 1. The fold change between patients and controls was expressed by the $2^{\Delta\Delta CT}$ method.

**Ethics statement**

The Medical Ethics Committee of Tianjin medical university general hospital approved the study protocol and informed written consent was obtained from all individuals. All study participants provided written informed consent for collection of blood samples, and for examination of clinical records relevant to the study.

**Meta-analysis**

Eligible studies were included if all criteria were met as follows: (1) studies aimed at
patients with IgAN, which were diagnosed with primary IgAN based on immunofluorescent and light microscopic; (2) the primary/original purpose of the study was to compare at least one of the following outcomes: the C1GALT1, C1GALT1C1 mRNA levels or β1, 3Gal-T activity; (3) all studies conducted in IgAN patients and controls. Four databases (PubMed, EMBASE, CNKI, Wanfang Medical Network) were searched from their earliest records to August 15th, 2018. No restriction on language or publication status was applied. The details of search keywords included “IgA glomerulonephritis”, “IgA nephropathy” “Glomerulonephritides”, “Berger’s disease”, “core-1β1-3 galactosyltransferase”, “C1GALT1 mRNA” “C1GALT1 expression”, “C1GALT1C1 mRNA” “C1GALT1C1 expression”, “β-galactosyltransferase expression “β-galactosyltransferase activity” and “controlled clinical trial”. Article without original data should be excluded. The main reasons for exclusion of trials are described in Additional Figure 1.

Two reviewers independently extracted the data from each study, collected data separately and finally summarized. The following related variables of patients were collected: country, mean age, male, sample size and detection index) (Table 2).

Risk of Bias
The Newcastle-Ottawa Scale (NOS) was used to assess the quality of included studies by judging them using three board perspectives: the selection of study groups, the comparability of study groups, and the measurement of exposure in study groups[7].

Statistical analysis
The differences in gene expression levels between groups were compared using ANOVA and p value < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 17.0 software. In the review, for the continuous measurement of C1GALT1, C1GALT1C1 expression and β1, 3Gal-T activity, we used the weighted mean difference and square deviation (SD) between groups. We analyzed heterogeneity beyond
chance using the $I^2$ statistic to describe the percentage of variability. We made graphic representations of potential publication bias using Begg’s Funnel plots of the natural logarithm of the RR versus its standard error (SE) and assessed them visually. A 2-sided p value less than 0.05 was considered statistically significant, and all statistical analyses were performed using Review Manager 5.3 software.

Results

Baseline clinical characteristics of patients with IgAN
There were 16 males and 14 females with average age of 39.5 years. The median of proteinuria was 1.32 g/d and mean eGFR was 85.45 mL/min/1.73 m$^2$ of IgAN patients on biopsy. And the grading of the pathological lesions by Oxford classification is shown in Table 3.

Patients with IgAN had low expression level of C1GALT1
The expression levels of C1GALT1 in B cells were detected in IgAN patients and healthy control. We found C1GALT1 expression levels were remarkably downregulated in IgAN patients (IgAN vs. controls: $1.01 \pm 0.19$ vs $1.43 \pm 0.11$, $p = 0.04$, Figure 1).

Expression of C1GALT1 related with the Gd-IgA1 levels
Using the GalNAc-specific monoclonal antibody KM55, we examined the plasma levels of Gd-IgA1 in patients with IgAN and healthy control. In our cohorts, the plasma level of Gd-IgA1 in patients with IgAN ranged from 8.55 to 14.48 U/mL, whereas it ranged from 3.97 to 12.15 U/mL in healthy control. We found that Gd-IgA1 levels were remarkable high in IgAN patients compared with healthy control ($p < 0.001$, Figure 2). And the mRNA levels of C1GALT1 were inversely correlated to Gd-IgA1 levels ($r = -0.33$, $p < 0.001$, Figure 3).

Meta-analysis
The literature search yielded 1052 articles, and eventually, six studies with 316 patients were included in our meta-analysis according to the inclusion criteria (Additional Figure 1). We included studies whose primary purpose was to elucidate the expression level and activity of C1GALT1 and the expression level of C1GALT1C1 in IgAN patients[5, 8–12]. Peripheral B lymphocyte was selected as target cell in 5 articles, and mononuclear cell in one article. Five studies compared the C1GALT1 and C1GALT1C1 mRNA expression levels and two measured the activity. Five studies were conducted in adult and one conducted in children. Of the contained six trials, four enrolled patients with IgAN and healthy control, two enrolled patients with IgAN, patients with non-IgAN glomerulonephritis and healthy control. The characteristics of the included studies were summarized in Table 2. These studies were performed from 1997 to 2016, with sample sizes ranging from 10 to 126.

Quality Assessment of Included Studies

The qualities of included studies, assessed with NOS (Newcastle-Ottawa Scale), are provided in Table 4. The mean total score was 5 with a range from 4 to 6.

C1GALT1 mRNA expression

We added own results to the final meta-analysis to elucidate the mRNA expression data of C1GALT1. Six articles including 316 participants that analyzed the expression of β1, 3Gal-T were included. There was no significant difference between IgAN patients and the total control group (weighted mean difference, -0.48 [95% CI -1.29 to 0.32], p = 0.24; I² = 93%, p for heterogeneity < 0.001) (Figure 4). Subgroup analysis was performed according to different control group and different cell source. Four studies compared mRNA expression level of C1GALT1 in 106 IgAN patients and 44 disease controls and five studies conducted in 160 IgAN patients and 139 healthy controls. There was no apparent disparity between IgAN patients and non-IgAN patients (weighted mean difference, 0.26 [95% CI -0.08 to 0.60], p = 0.14; I² = 0%, p for heterogeneity = 0.89) and healthy controls.
(weighted mean difference, -0.62 [95% CI -1.59 to 0.36], p = 0.21; I² = 93%, p for heterogeneity < 0.001) (Figure 5).

In circulation, B lymphocytes are the major cells for IgA1 production. To explore the causal factor of the lymphocytes abnormality in patients with IgAN, in terms of β1, 3 galactosyltransferase induced Gd-IgA1 production, we detected the mRNA expression of C1GALT1 in B lymphocytes. A total of 4 studies enrolled 81 patients and 88 controls. Finding for this outcome was that patients with IgAN had low levels of C1GALT1 gene expression in the B lymphocytes compared to control (weighted mean difference, 0.39 [95% CI 0.08 to 0.69], p = 0.01; I² = 96%, p for heterogeneity < 0.001) (Figure 6).

**β1, 3Gal-T activity**

Comparison of β1, 3Gal-T activity was reported in 2 trials including 46 persons, the result showed patients with IgAN had low levels of β1, 3Gal-T activity in the B cells compared to control (weighted mean difference, -2.43 [95% CI -4.33 to -0.52], p = 0.01; I² = 80%, p for heterogeneity = 0.03) (Figure 7).

**C1GALT1C1 expression**

We also explored the expression of C1GALT1C1 in different groups. There was no significant difference between IgAN patients and the total control group (weighted mean difference, -0.68 [95% CI -1.61 to 0.25], p = 0.15; I² = 93%, p for heterogeneity < 0.001) (Supplement Figure 1). And the same result occurred between IgAN patients and non-IgAN patients (weighted mean difference, 0.20 [95% CI -0.99 to 0.59], p = 0.62; I² = 80%, p for heterogeneity = 0.007) and healthy control (weighted mean difference, -0.80 [95% CI -1.90 to 0.29], p = 0.39; I² = 81%, p for heterogeneity = 0.002, Supplement Figure 2).

Even in the B lymphocytes the levels of C1GALT1C1 gene expression that between IgAN and the control group had no significant difference (weighted mean difference, -0.34 [95% CI
CI -1.13 to 0.44], p = 0.39; I² = 81%, p for heterogeneity = 0.002, Supplement Figure 3).
In the meantime, subgroup meta-analysis was conducted between Chinese and UK subjects. The result showed there were no different from the levels between different ethnic population (weighted mean difference, -0.66 [95% CI -2.09 to 0.77] vs -0.65 [95% CI -1.55 to 0.25], p for heterogeneity = 0.99, Supplement Figure 4).

**Risk of bias**

Formal statistical test showed that there was no publication bias in the expression of C1GALT1 compared between IgAN patients and total control (Begg’s test p = 0.452), which was showed in Additional Figure 2.

**Discussion**

In recent years, the role of galactose-deficiency of IgA1 in IgAN is widely recognized, thus how to cause the occurrence of galactose-deficiency has become the focus of the research[13]. It demonstrates that common variation at C1GALT1 influences Gd-IgA1 level in IgAN[3, 14]. In this study we found expression levels of C1GALT1 were remarkably downregulated in IgAN patients and negatively correlated with higher levels of Gd-IgA1. Subsequent meta-analysis validated the low expression of C1GALT1 only in B cells in patients with IgAN.

The mechanisms leading to aberrant glycosylation of IgA1 in IgAN have been studied extensively; so far, two genome-wide association studies (GWAS) conducted in IgAN populations identified C1GALT1 that strongly associated with levels of Gd-IgA1, however, whether the mRNA level of C1GALT1 was associated with Gd-IgA1 levels in patients with IgAN needed to be determined. In the present study, we observed downregulated C1GALT1 mRNA’s expression in B lymphocytes in IgAN patients and patients with low C1GALT1 levels showed high levels of Gd-IgA1 in vivo. In circulation, CD19+ B lymphocytes are the
major cells for IgA1 production. A study examined tonsillar B lymphocytes of IgAN showed the expression of C1GALT1 was significantly decreased in tonsillar CD19 positive B lymphocytes from IgAN patients compared to the control[15]. It might imply that B lymphocytes play an important role in deciding the C1GALT1 mRNA level, which suggested an abnormality of B lymphocytes in IgAN. Yamada et al found IL-4 stimulation significantly decreased the mRNA levels of both C1GALT1 and Cosmc[5]. In Suzuki et al showed IL-6 stimulation of IgA1-producing cells from IgAN patients accentuates galactose-deficiency of IgA1 O-glycans[16]. Investigation of the actual reason underlying the expression deficiency of C1GALT1 may shed light on the mechanism of IgAN and help to find new therapy of this disease. Many experts hold the reviews that down-regulation of C1GALT1 expression or activity of β1, 3Gal-T in B lymphocytes, which inducing increased production of aberrantly glycosylated IgA1 molecules, ultimately contributed to IgAN pathogenesis[17]. Thus, according to these studies and views, it seems to closely show that this downregulation might be one of the fundamental pathogenic abnormalities in IgAN.

In the meta-analysis, patients with IgAN had low β1, 3Gal-T activity in the B lymphocytes compared to control group. However, it is not clarified whether abnormalities of IgA1 O-glycosylation was a result from reduced β1, 3Gal-T activity, there is a paucity of information on the regulation of activity of this glycosyltransferase. Cosmc, encoded by C1GALT1C1, is core 1 beta-3-galactosyltransferase specific chaperone, and important for IgA1 glycosylation[18]. The expression of C1GALT1C1 was closely related to the activity of β1, 3Gal-T, and it was previously reported to be down-regulated and associated with IgA1 glycosylation[19]. Therefore we analyzed the expression of C1GALT1C1 by meta-analysis, the result showed that there was no significant difference between IgAN patients and the total control group. Furthermore, the results were not modified by different ethnic
population, different control group and different cell source. Further studies were needed for a better understanding of the potential mechanism of the change of β1, 3Gal-T activity.

Limitations

Our study does, however, have several limitations. Firstly, because of the lack of sufficient data, a subgroup analysis explored the heterogeneity between C1GALT1 and the pathogenesis of IgAN is not conducted. Secondly, the specific quantification methods of qPCR experiments and internal control differed between studies, which may affect the effect sizes. Thirdly, the sample size of our study is small and the involved studies have poor quality assessment. We will further expand the sample size to verify the expression of C1GALT1 in IgA patients and its relationship with Gd-IgA1 levels.

Conclusion

We found expression level of C1GALT1 was remarkably downregulated in IgAN patients and negatively correlated with higher levels of Gd-IgA1. Subsequent meta-analysis validated the low C1GALT1 expression and activity of β1, 3Gal-T in B lymphocytes in patients with IgAN. Furthermore, the results showed there were no apparent disparities between IgAN and control groups in the aspect of C1GALT1C1 expression, even in peripheral B lymphocytes. Together, these results revealed an aberrant β1, 3Gal-T expression and activity in B cells from IgAN patients, which could be identified as potential targets for future disease specific therapy of IgAN.

Abbreviations

IgAN: IgA nephropathy

Gd-IgA1: Galactose-deficient IgA1

β1, 3-galactosyltransferase: β1, 3Gal-T
PBMC: Peripheral blood mononuclear cell

ESRD: End-stage renal disease

SNPs: Single nucleotide polymorphisms

eGFR: Estimated glomerular filtration rate

GWAS: Genome-wide association study

NOS (Newcastle-Ottawa Scale)

Declarations

**Ethics approval and consent to participate**

The Medical Ethics Committee of Tianjin medical university general hospital approved the study protocol and informed written consent was obtained from all individuals. All study participants provided written informed consent for collection of blood samples, and for examination of clinical records relevant to the study.

**Consent for publication**

Not applicable.

**Availability of data and material**

Raw data used during the current study are available from the corresponding author on reasonable request for non-commercial use.

**Competing Interests**

The authors declare that they have no competing interests.

**Funding**

This study is supported by the National Natural Science Foundation (81600552) and the General Hospital of Tianjin Medical University Youth Incubation Foundation (ZYYFY2015001).

**Authors’ contributions**

LYX conceived and designed the study. XY and LLN screened the full text, performed
statistical analyses, and drafted the manuscript. ZYR and WFH performed data extraction and quality assessment. All authors read the manuscript and approved the final version.

Acknowledgements

Not applicable.

References

1. Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy. J Nephrol. 2016. 29(1): 13–9.

2. Vecchio M, Bonerba B, Palmer SC, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2015. (8): CD003965.

3. Gale DP, Molyneux K, Wimbury D, et al. Galactosylation of IgA1 is Associated with Common Variation in C1GALT1. J Am Soc Nephrol. 2017. 28(7): 2158–2166.

4. Xiao J, Wang M, Xiong D, et al. TGF-β1 mimics the effect of IL-4 on the glycosylation of IgA1 by downregulating core 1 β1, 3-galactosyltransferase and Cosmc. Mol Med Rep. 2017. 15(2): 969–974.

5. Qin W, Zhou Q, Yang LC, et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med. 2005. 258(5): 467–77.

6. Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015. 30(8): 1315–1321.

7. Ofek SN, Rao S, Patole S. Efficacy of interventions to improve hand hygiene compliance in neonatal units: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2015. 34(5): 887-97.

8. Shao JW. IL-4, C1GALT1 and COSMC Expression in Severe IgA Nephropathy and the Prognosis Analysis of the Disease. Labeled Immunoassays & Clinical Medicine.
9. Cai Y, Jiang XY, Chen SM, et al. Expression of β1,3 Galactosyltransferase mRNA and Cosmc mRNA in Peripheral B Lymphocyte of Patients with IgA Nephropathy. Journal of Applied Clinical Pediatrics. 2010.25(16): 1254-1256.

10. Buck KS, Smith AC, Molyneux K, El-Barbary H, Feehally J, Barratt J. B-cell O-galactosyltransferase activity, and expression of O-glycosylation genes in bone marrow in IgA nephropathy. Kidney Int. 2008. 73(10): 1128-36.

11. Boyd, Fiona JK. Glycosyltransferase expression in IgA+ B cells in IgA nephropathy. 2014.

12. Allen AC, Topham PS, Harper SJ, Feehally J. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997. 12(4): 701-6.

13. McCluer R, Koul O. [Glycosyltransferase inhibitors and study of UDP-galactose-globoside galactosyltransferase]. Biokhimiia. 1995. 60(3): 419–31.

14. Inoue T, Sugiyama H, Hiki Y, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010. 136(3): 447-455.

15. Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010. 25(12): 3890-7.

16. Novak J, Raskova KL, Suzuki H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant. 2011. 26(11): 3451-7.

17. Xie LS, Qin W, Fan JM, Huang J, Xie XS, Li Z. The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy. Clinical & Investigative Medicine. 2010. 33(1): E5-13.
18. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc Natl Acad Sci U S A. 2002; 99(26):16613–8.

19. Xie LS, Qin W, Fan JM, Huang J, Xie XS, Li Z. The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy. Clin Invest Med. 2010;33:E5–13.

Tables

Due to technical limitations, tables are only available as a download in the supplemental files section

Figures

![Figure 1](image)

Expression level of C1GALT1 gene in IgAN and Control
Figure 2
Gd-IgA1 levels in IgAN and Healthy Control

Figure 3
Expression of C1GALT1 related with the Gd-IgA1 levels
### C1GALT1 Expression IgAN VS Total Control

**Figure 4**

Comparison of the expression of C1GALT1 between IgAN and Total Control
### Figure 5

Comparison of the expression of C1GALT1 between IgAN and Non-IgAN (A) and Healthy Control (B)
### C1GALT1 Expression in PB | IgAN VS Control

Comparison of the expression of C1GALT1 in B cells between IgAN and Total Control

| Study     | IgAN Mean | IgAN SD | IgAN N | Control Mean | Control SD | Control N | Weight | IV, Fixed, 95% CI | IV, Fixed, 95% CI |
|-----------|-----------|---------|--------|--------------|------------|-----------|--------|-------------------|-------------------|
| Boyd 2014[10] | 8.2       | 0.2     | 5      | 8.04         | 0.5        | 5         | 0.21   | -1.03, 1.46       |                   |
| Burt 2008[8]  | 1.17      | 0.07    | 12     | 1.12         | 0.02       | 13        | 1.32   | 0.96, 1.78        |                   |
| Cai 2010[5]   | 0.81      | 0.17    | 23     | 0.81         | 0.2        | 33        | 0.37   | 0.17, 0.90        |                   |
| Lin 2018      | 1.01      | 0.19    | 36     | 1.41         | 0.11       | 30        | 1.93   | -3.33, -1.35      |                   |
| Qin 2005[5]   | 1.22      | 0.36    | 41     | 0.6          | 0.19       | 27        | 2.26   | 1.54, 2.94        |                   |
| Total (95% CI)| 111       |         | 118    | 100.0%       |            |           | 0.39   | 0.08, 0.69        |                   |

Heterogeneity: Chi² = 107.10, df = 4 (P < 0.001); Ψ = 96%

Test for overall effect: Z = 2.49 (P = 0.01)
**Figure 7**

Comparison of the activity of β1, 3Gal-T in B cells between IgAN and Control

**Supplementary Files**

This is a list of supplementary files associated with the primary manuscript. Click to download.

- Supplement Figure 2.pptx
- Additional Figure 2.pptx
- Supplement Figure 1.pptx
- Additional Figure 1.pptx
- Table 1.docx
- Table 2.docx
- Supplement Figure 3.pptx
- Supplement Figure 4.pptx
- Table 4.docx
- Table 3.docx